Page 8 - 89Zr-Immuno-PET:Towards a Clinical Tool to Guide Antibody-based Therapy in Cancer
P. 8
CONTENTS
Chapter 1
Part I
Chapter 2
Chapter 3
Chapter 4
Part II
Chapter 5
Chapter 6
General introduction 9
Feasibility of 89Zr-immuno-PET 19
Radiation dosimetry of 89Zr-labeled chimeric 21 monoclonal antibody U36 as used for immuno-PET in
head and neck cancer patients.
J Nucl Med. 2009;50:1828-36
Performance of immuno-positron emission 43 tomography with zirconium-89-labeled chimeric
monoclonal antibody U36 in the detection of lymph
node metastases in head and neck cancer patients.
Clin Can Res. 2006;12:2133-40
Immuno-positron emission tomography with 63 Zirconium-89-labeled monoclonal antibodies in
oncology: what can we learn from initial clinical trials?
Front Pharmacol. 2016;24;7:131
Validation of 89Zr-immuno-PET 95
Noise-induced variability of immuno-PET with 97 Zirconium-89-labeled antibodies: an analysis based on count-reduced clinical images.
Mol Imaging Biol. 2018;20:1025-1034
Interobserver reproducibility of tumor uptake 121 quantification with 89Zr-immuno-PET: a multicenter
analysis.
Eur J Nucl Med Mol Imaging. 2019; 2019;46:1840-1849
